The accelerated development in the treatment of metastatic melanoma, both in molecular targeted therapy and immunotherapy, is already starting to impact on adjuvant therapy in stage III melanoma. Following the approval of ipilimumab for adjuvant therapy in melanoma, clinical trials assessing other checkpoint modulators and MAPK pathway inhibitors as adjuvant treatments for melanoma are currently ongoing. As results from these trials mature in the next few years, a change in the landscape of adjuvant treatment for melanoma is expected, resulting in new challenges in treatment decisions such as optimizing patients selection through predictive and prognostic biomarkers, and management of treatment related adverse events, in particular immune related toxicities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094670 | PMC |
| http://dx.doi.org/10.2217/mmt-2016-0002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extramedullary plasmacytoma with the uvula as first affected site: A case report.
World J Clin Oncol
January 2025
Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China.
Background: Extramedullary plasmacytoma (EMP) represents one of the rarer forms of plasma cell malignancies, capable of impacting a variety of tissues and organs throughout the body. The majority of EMP cases are predominantly found in the head and neck region, especially within the laryngopharynx, as well as in the gastrointestinal tract. While there have been documented instances of oropharyngeal involvement in EMP cases in the academic literature, it is important to note that EMP specifically affecting the uvula is exceedingly uncommon.
View Article and Find Full Text PDFManagement of intrahepatic cholangiocarcinoma: a review for clinicians.
Gastroenterol Rep (Oxf)
January 2025
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy that arises from second-order biliary epithelial cells. Its incidence is gradually increasing worldwide. Well-known risk factors have been described, although in many cases, they are not identifiable.
View Article and Find Full Text PDFThe value of a metabolic and immune-related gene signature and adjuvant therapeutic response in pancreatic cancer.
Front Genet
January 2025
Department of Oncology, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, China.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by a dismal prognosis. Treatment outcomes exhibit substantial variability across patients, underscoring the urgent need for robust predictive models to effectively estimate survival probabilities and therapeutic responses in PDAC.
Methods: Metabolic and immune-related genes exhibiting differential expression were identified using the TCGA-PDAC and GTEx datasets.
Papillary Tumor of the Pineal Region Treated With Surgery and Postoperative Radiotherapy: A Case Report.
Cureus
January 2025
Radiation Oncology, Centre Hospitalier Affilié Universitaire Régional, Trois-Rivieres, CAN.
Papillary tumors of the pineal region (PTPR) are extremely rare malignancies that make up less than 0.1% of primary brain tumors. They are usually treated with surgery and adjuvant tumor bed radiotherapy (RT).
View Article and Find Full Text PDFEfficacy of Bacillus clausii UBBC-07 and Bacillus coagulans Unique IS-2 in Mitigating Pulmonary Parameters in Patients With Moderate COVID-19 Symptoms.
Cureus
December 2024
Department of Pharmacology, Employees' State Insurance Corporation (ESIC) Medical College and Hospital, Hyderabad, IND.
Probiotics have shown efficacy in preventing and reducing infections caused by common viruses, including rotavirus, norovirus, hepatitis, human papillomavirus (HPV), human immunodeficiency virus (HIV), and herpes simplex virus (HSV). A randomized, double-blind, placebo-controlled, three-arm parallel-group study was conducted on 56 patients with moderate COVID-19 symptoms. Patients were randomly assigned to one of the three groups: standard treatment combined with UBBC-07, standard treatment combined with Unique IS-2, or standard treatment with a placebo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!